Lipitor — Net Sales
Viatris Lipitor — Net Sales increased by 22.4% to $462.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.1%, from $388.00M to $462.00M. Over 4 years (FY 2021 to FY 2025), Lipitor — Net Sales shows relatively stable performance with a -1.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong brand loyalty or successful lifecycle management, while a decrease reflects the expected erosion of market share due to generic competition or therapeutic substitution.
Detailed definition
This metric represents the total revenue generated from the sale of Lipitor, a cholesterol-lowering statin medication, a...
Peer comparison
Comparable to revenue metrics for mature, off-patent branded drugs at other large-cap pharmaceutical companies, often evaluated based on the rate of revenue decay.
vtrs_segment_lipitor_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $398.30M | $410.00M | $390.30M | $440.10M | $405.60M | $420.40M | $369.10M | $417.90M | $380.00M | $381.60M | $379.80M | $388.90M | $348.40M | $375.60M | $355.90M | $388.00M | $387.90M | $396.10M | $377.30M | $462.00M |
| QoQ Change | — | +2.9% | -4.8% | +12.8% | -7.8% | +3.6% | -12.2% | +13.2% | -9.1% | +0.4% | -0.5% | +2.4% | -10.4% | +7.8% | -5.2% | +9.0% | -0.0% | +2.1% | -4.7% | +22.4% |
| YoY Change | — | — | — | — | +1.8% | +2.5% | -5.4% | -5.0% | -6.3% | -9.2% | +2.9% | -6.9% | -8.3% | -1.6% | -6.3% | -0.2% | +11.3% | +5.5% | +6.0% | +19.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's lipitor — net sales?
- Viatris (VTRS) reported lipitor — net sales of $462.00M in Q1 2026.
- How has Viatris's lipitor — net sales changed year-over-year?
- Viatris's lipitor — net sales increased by 19.1% year-over-year, from $388.00M to $462.00M.
- What is the long-term trend for Viatris's lipitor — net sales?
- Over 4 years (2021 to 2025), Viatris's lipitor — net sales has grown at a -1.8% compound annual growth rate (CAGR), from $1.66B to $1.55B.
- What does lipitor — net sales mean?
- The total revenue earned from selling the branded cholesterol medication Lipitor.